Next Article in Journal
Essential Oils Modulate Gene Expression and Ochratoxin A Production in Aspergillus carbonarius
Previous Article in Journal
A Simple Luminescent Adenylate-Cyclase Functional Assay for Evaluation of Bacillus anthracis Edema Factor Activity
Case Report

A Single Dose of ViperfavTM May Be Inadequate for Vipera ammodytes Snake Bite: A Case Report and Pharmacokinetic Evaluation

1
Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb, Rockefellerova 10, HR-10000 Zagreb, Croatia
2
Centre for Clinical Toxicology and Pharmacology, University Medical Centre Ljubljana, Zaloška cesta 7, 1000 Ljubljana, Slovenia
3
Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Zaloška cesta 4, 1000 Ljubljana, Slovenia
4
Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Jamova 39, 1000 Ljubljana, Slovenia
5
Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, 1000 Ljubljana, Slovenia
*
Author to whom correspondence should be addressed.
These authors contribute equally to this work.
Academic Editor: Wayne Hodgson
Toxins 2016, 8(8), 244; https://doi.org/10.3390/toxins8080244
Received: 30 June 2016 / Accepted: 11 August 2016 / Published: 19 August 2016
(This article belongs to the Section Animal Venoms)
ViperfavTM is a commercial F(ab’)2 antivenom prepared against European vipers venom. It is safe and effective for treating envenomation caused by Vipera aspis and Vipera berus. Therapeutic efficacy for treating Vipera ammodytes ammodytes (V. a. ammodytes) envenoming has not been yet described, although protective efficacy has been demonstrated in preclinical studies. We report on a 32-year-old man bitten by V. a. ammodytes who was treated with Viperfav™. Viperfav™ promptly reduced local extension and improved systemic pathological signs, but 24 h after the incident a recurrence of thrombocytopenia occurred despite a favorable pharmacokinetic profile with systemic clearance (1.64 (mL·h−1)·kg−1) and elimination half-life (97 h) among the highest ever reported. The recommended dose of Viperfav™ for V. aspis and V. berus bites may be inadequate for serious V. a. ammodytes envenomations. Following V. a. ammodytes bite, serial blood counts and coagulation profiles should be performed to help guide Viperfav™ treatment, along with supplemental administration as indicated. View Full-Text
Keywords: Vipera ammodytes ammodytes envenomation; Viperfav™ antivenom treatment; F(ab’)2 antivenom pharmacokinetics Vipera ammodytes ammodytes envenomation; Viperfav™ antivenom treatment; F(ab’)2 antivenom pharmacokinetics
Show Figures

Graphical abstract

MDPI and ACS Style

Kurtović, T.; Brvar, M.; Grenc, D.; Lang Balija, M.; Križaj, I.; Halassy, B. A Single Dose of ViperfavTM May Be Inadequate for Vipera ammodytes Snake Bite: A Case Report and Pharmacokinetic Evaluation. Toxins 2016, 8, 244. https://doi.org/10.3390/toxins8080244

AMA Style

Kurtović T, Brvar M, Grenc D, Lang Balija M, Križaj I, Halassy B. A Single Dose of ViperfavTM May Be Inadequate for Vipera ammodytes Snake Bite: A Case Report and Pharmacokinetic Evaluation. Toxins. 2016; 8(8):244. https://doi.org/10.3390/toxins8080244

Chicago/Turabian Style

Kurtović, Tihana, Miran Brvar, Damjan Grenc, Maja Lang Balija, Igor Križaj, and Beata Halassy. 2016. "A Single Dose of ViperfavTM May Be Inadequate for Vipera ammodytes Snake Bite: A Case Report and Pharmacokinetic Evaluation" Toxins 8, no. 8: 244. https://doi.org/10.3390/toxins8080244

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop